首頁 > 市場調查報告書 > 製藥

以基因為基之藥物開發生物標記

市場調查報告書

商品編碼

2126347

基因生物標記市場：策略性洞察與預測（2026-2035）

Genomic Biomarkers Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月04日 | 出版商:

Knowledge Sourcing Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

基因生物標記市場預計將從 2026 年的 116.7 億美元成長到 2035 年的 201.2 億美元，複合年成長率為 6.2%。

基因生物標記市場正經歷重大變革，其驅動力來自精準醫療的模式轉移以及人們對基因組資訊在個人化臨床決策中關鍵作用的日益重視。隨著醫療服務提供者採用基於基因組的精準醫療策略，而非僅僅依賴傳統的表現型評估，全面的基因組分析正日益融入常規臨床實踐，從而定義著該市場的演變。先進的定序技術、生物資訊學和人工智慧的融合，正推動著更全面、更標準化的基因生物標記的發現和檢驗。基因生物標記基因生物標記被應用於醫療保健系統的多個疾病領域，因為它們能夠提供分子證據，支持患者選擇、疾病監測、治療反應預測以及抗藥性機制的識別。製藥公司正在將基因生物標記整合到其臨床開發項目中，以簡化臨床試驗流程並提高法規核准率。隨著對次世代定序基礎設施、液態生物檢體技術和人工智慧分析工具的大量投資，基因生物標記正在成為腫瘤學、罕見疾病、感染疾病、循環系統疾病和神經系統疾病領域的重要基礎設施要素。

市場促進因素

精準腫瘤學的日益普及是基因生物標記市場的主要驅動力。精準腫瘤學依賴基因生物標記來識別影響治療選擇的分子突變。由於標靶治療的處方需要檢驗的生物標記證據，醫院和癌症中心擴大採用全面的基因組分析。這種依賴性減少了經驗性治療方法，同時提高了多種癌症類型的患者分層。同時，製藥公司也正在擴大以生物標記主導的臨床試驗，增加了對標準化基因組檢測平台的需求。因此，診斷和治療的整合正在不斷推進，增強了長期市場滲透率，並推動了基因生物標記應用的持續成長。次世代定序(NGS) 基礎設施的擴展透過實現全面生物標記的發現，進一步加速了市場成長。 NGS 提供高度擴充性的基因組分析，可以同時評估眾多臨床相關的突變。與序貫檢測相比，全面的分子表徵提高了診斷準確性，促使醫療機構擴展其定序能力。隨著基因組資料集的不斷擴展，解讀方面的挑戰也隨之而來，這需要先進的生物資訊能力。為此，診斷公司正在將自動化分析軟體整合到其定序平台中，以簡化臨床工作流程。這項技術生態系統持續支持基因生物標記的廣泛應用。伴隨診斷對於標靶治療的開發和監管合規性至關重要。許多標靶治療需要經過驗證的伴隨檢驗來識別合格的患者，然後再開始治療。隨著監管機構越來越重視基於生物標記的臨床證據，製藥公司在治療藥物和基因組檢測的共同開發方面進行了越來越多的合作。當分子標靶無法確定時，藥物研發人員將面臨研發複雜性增加的挑戰。診斷製造商正在擴大與製藥公司的合作，以因應臨床開發各階段的這項需求。這些合作提升了基因生物標記在整個藥物價值鏈中的戰略價值。群體基因組分析計畫正在推動臨床證據的產生和生物標記的檢驗。各國進行的基因組醫學舉措正在產生大量的基因組資料集，從而改善了不同族群中生物標記的檢驗。隨著基因組證據支持早期診斷和個人化治療策略，世界各國政府都在加強對精準醫療計畫的投入。研究機構也正在擴大多中心基因組研究合作，以提高臨床代表性和分析的穩健性。

市場限制因素

定序基礎設施、生物資訊整合和臨床解讀的高昂實施成本持續限制小規模醫療機構對定序技術的應用。先進技術所需的大量資金投入對預算有限的機構而言是一大障礙。儘管臨床證據不斷增加，但不同醫療機構對綜合基因組檢測的報銷政策差異限制了其常規應用。保險覆蓋範圍的區域差異給診斷服務提供者帶來不確定性，並限制了患者的就醫途徑。由於證據有限，醫生難以對某些基因組學觀察充滿信心，因此對意義不明突變的臨床解讀仍然是一個挑戰。某些基因組突變的不確定性為臨床決策帶來了挑戰。此外，複雜且區域差異大的法規也為尋求將新型基因生物標記解決方案商業化的製造商帶來了合規負擔。

市場定義和範圍
行業概覽
產業變化
主要市場趨勢
市場規模表現分析
市場預測分析
基因生物標記的疾病負擔與臨床意義
疾病流行率的流行病學分析
已確診患者族群的分析
精準醫療實施現狀
對所進行的生物標記檢測數量進行分析
伴隨診斷的現狀
按治療領域分類的臨床效用

第4章市場動態

市場促進因素
市場限制因素
市場機遇
市場挑戰

第5章行業情勢

產業價值鏈分析
定價分析
還款狀態

第6章：創新趨勢

新基因組技術
生物標記發現與檢驗的趨勢
伴隨診斷創新
臨床試驗分析
基於基因生物標記的診斷方法流程分析
將人工智慧整合到基因生物標記的發現與解讀中
多體學與數位健康的整合
技術藍圖

第7章監理情勢

法律規範
核准流程
合規要求

第8章全球基因生物標記市場：展望分析

分析：依生物標記類型
分析：按技術平台
分析：檢體類型
分析：透過臨床應用
分析：透過測試方法
分析：按治療領域

第9章全球基因生物標記市場：細分市場分析

依生物標誌類型
- DNA生物標記
- RNA生物標記
- 其他基因生物標記
透過技術
- 次世代定序（NGS）
- 聚合酵素鏈鎖反應（PCR）
- 微陣列分析
- 其他基因組技術
依檢體類型
- 組織切片檢查
- 液態生物檢體
- 唾液/口腔黏膜拭子
- 其他生物檢體
透過臨床應用
- 瘤
- 罕見遺傳疾病
- 心血管疾病
- 神經病變
- 感染疾病
- 自體免疫疾病
- 其他臨床用途
最終用戶
- 醫院
- 臨床診斷檢測實驗室
- 學術研究機構
- 其他

第10章全球基因生物標記市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章全球基因生物標記市場：國別分析

美國
加拿大
德國
英國
法國
義大利
西班牙
日本
中國
印度
韓國
澳洲
巴西
墨西哥
沙烏地阿拉伯
南非

第12章競爭格局

市佔率分析
策略趨勢
併購、合作與聯盟
新產品發布

第13章：公司簡介

Illumina, Inc.
F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific Inc.
Natera
Tempus AI
Guardant Health, Inc.
Exact Sciences Corporation
Grail
Bio-Rad Laboratories, Inc.
Natera, Inc.

第14章全球基因生物標記市場：商業預測分析

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI061617234

The Genomic Biomarkers Market is predicted to increase at a CAGR of 6.2%, from USD 11.67 billion in 2026 to USD 20.12 billion in 2035.

The genomic biomarkers market is undergoing significant transformation driven by the paradigm shift toward precision medicine and the growing recognition that genomic information is essential for individualized clinical decision-making. The market's evolution is characterized by the increasing integration of comprehensive genomic profiling into routine clinical practice, as healthcare providers adopt precision medicine strategies that rely on genomic information rather than conventional phenotypic assessment alone. The convergence of advanced sequencing technologies, bioinformatics, and artificial intelligence is enabling more comprehensive and standardized genomic biomarker discovery and validation. Healthcare systems are incorporating genomic biomarkers across multiple disease areas because they provide molecular evidence that supports patient selection, disease monitoring, treatment response prediction, and identification of therapeutic resistance mechanisms. Pharmaceutical companies are embedding genomic biomarkers throughout clinical development programs to improve trial efficiency and regulatory success. The market is witnessing significant investment in next-generation sequencing infrastructure, liquid biopsy technologies, and AI-enabled interpretation tools, positioning genomic biomarkers as a critical infrastructure component across oncology, rare diseases, infectious diseases, cardiovascular medicine, and neurological disorders.

Market Drivers

The increasing adoption of precision oncology represents the primary driver for the genomic biomarkers market. Precision oncology relies on genomic biomarkers to identify molecular alterations that influence treatment selection. Hospitals and cancer centers are increasingly incorporating comprehensive genomic profiling because targeted therapies require validated biomarker evidence before prescription. This dependency reduces empirical treatment approaches while improving patient stratification across multiple cancer types. Pharmaceutical companies are simultaneously expanding biomarker-driven clinical trials, which increases demand for standardized genomic testing platforms. The resulting integration of diagnostics and therapeutics strengthens long-term market adoption, resulting in sustained growth in genomic biomarker utilization. The expansion of next-generation sequencing infrastructure is further accelerating market growth by enabling comprehensive biomarker discovery. NGS provides scalable genomic analysis that supports simultaneous evaluation of numerous clinically relevant variants. Healthcare providers are expanding sequencing capacity because comprehensive molecular characterization improves diagnostic accuracy compared with sequential testing methods. Larger genomic datasets create interpretation challenges that require advanced bioinformatics capabilities. Diagnostic developers are responding by integrating automated analysis software with sequencing platforms to improve clinical workflow efficiency. This technological ecosystem supports continued growth in genomic biomarker utilization. Companion diagnostics are becoming essential for targeted drug development and regulatory alignment. Many targeted therapies require validated companion diagnostics to identify eligible patients before treatment initiation. Pharmaceutical sponsors are increasingly co-developing therapeutics and genomic assays because regulatory agencies emphasize biomarker-supported clinical evidence. Drug developers face higher development complexity when molecular selection is absent. Diagnostic manufacturers are expanding partnerships with pharmaceutical companies to address this requirement throughout clinical development. These collaborations reinforce the strategic value of genomic biomarkers across the pharmaceutical value chain. Population genomics programs are increasing clinical evidence generation and biomarker validation. National genomic medicine initiatives generate extensive genomic datasets that improve biomarker validation across diverse populations. Governments are investing in precision medicine programs because genomic evidence supports earlier diagnosis and individualized treatment strategies. Research organizations are expanding multicenter genomic collaborations to improve clinical representation and analytical robustness.

Market Restraints

High implementation costs associated with sequencing infrastructure, bioinformatics integration, and clinical interpretation continue to limit adoption among smaller healthcare institutions. The significant financial investment required for advanced technologies creates barriers for facilities with limited budgets. Variability in reimbursement policies for comprehensive genomic testing restricts routine utilization across several healthcare systems despite increasing clinical evidence. Inconsistent coverage across regions creates uncertainty for diagnostic providers and limits patient access. Clinical interpretation of variants of uncertain significance remains challenging because limited evidence reduces physician confidence in certain genomic findings. The uncertainty surrounding some genomic variants creates challenges for clinical decision-making. Regulatory complexities across different jurisdictions create compliance burdens for manufacturers seeking to commercialize new genomic biomarker solutions.

Technology and Segment Insights

The technology landscape is characterized by the growing importance of comprehensive genomic profiling platforms and AI-enabled interpretation. DNA biomarkers constitute the largest segment because permanent genomic alterations provide highly reliable molecular evidence for disease diagnosis, prognosis, and therapeutic selection. Healthcare providers are increasingly utilizing comprehensive DNA sequencing because targeted therapies require identification of actionable genomic variants before treatment initiation. NGS is expanding comprehensive biomarker discovery and clinical testing capabilities. PCR remains important for focused mutation detection where rapid turnaround is prioritized. Microarray analysis supports large-scale genomic screening for copy number variations and gene expression profiling. The segment analysis reveals that tissue biopsy remains the clinical reference standard because direct tumor sampling enables comprehensive genomic characterization with high analytical confidence. Oncology centers are continuing to depend on tissue-derived genomic analysis because regulatory approvals for numerous companion diagnostics originate from tissue validation studies. Liquid biopsy is expanding for minimally invasive testing when tissue samples are limited, enabling repeated genomic assessment without invasive tissue collection. Oncology dominates clinical utilization because genomic biomarkers determine eligibility for an expanding portfolio of targeted therapies and immunotherapies. Cancer centers are incorporating comprehensive genomic profiling into routine practice because molecular characterization improves therapeutic precision and clinical outcomes. Rare genetic diseases represent a major application because pathogenic genomic variants frequently establish definitive diagnoses that conventional diagnostic methods cannot achieve. Cardiovascular medicine is gradually expanding genomic biomarker utilization for inherited cardiomyopathies, arrhythmias, and lipid metabolism disorders. Neurological diseases increasingly incorporate genomic testing to characterize inherited neurodegenerative conditions. Clinical diagnostic laboratories represent the leading end-user segment, with hospitals and academic research institutes expanding testing capabilities. The integration of AI is becoming increasingly important because large sequencing datasets require efficient computational analysis to generate clinically actionable insights. Healthcare laboratories are implementing AI tools because manual variant interpretation limits operational scalability.

Competitive and Strategic Outlook

The competitive landscape features established life science and diagnostics companies alongside specialized precision medicine and AI-driven analytics providers. Illumina distinguishes itself through global leadership in NGS technologies that form the technological foundation of numerous genomic biomarker applications, providing integrated sequencing instruments, consumables, informatics software, and clinical sequencing solutions that support research, translational medicine, and routine molecular diagnostics. Roche maintains a differentiated market position by integrating pharmaceutical development with molecular diagnostics through its companion diagnostic strategy, developing genomic biomarker assays alongside targeted therapeutics, enabling synchronized regulatory submissions and clinical implementation. Thermo Fisher Scientific offers a comprehensive molecular diagnostics ecosystem encompassing sequencing platforms, PCR technologies, sample preparation systems, reagents, and bioinformatics solutions, supporting genomic biomarker discovery as well as clinical implementation across pharmaceutical, academic, and healthcare laboratories. Guardant Health differentiates itself through leadership in liquid biopsy technologies utilizing circulating tumor DNA for comprehensive genomic profiling and minimal residual disease assessment, focusing on non-invasive cancer diagnostics that support therapy selection, disease monitoring, and recurrence detection. Exact Sciences focuses on molecular diagnostics that support early cancer detection, precision oncology, and treatment monitoring through advanced genomic technologies, continuing to expand its oncology portfolio by integrating genomic biomarker testing with cancer screening and diagnostic services. Tempus AI combines AI, clinical data analytics, and comprehensive genomic profiling to improve precision medicine decision-making, integrating molecular sequencing with large-scale clinical datasets. Companies are pursuing product portfolio expansion through innovation in NGS platforms, liquid biopsy assays, and AI-enabled interpretation tools. Strategic collaborations between diagnostic manufacturers and pharmaceutical companies are increasing, driven by the need for companion diagnostic development alongside targeted therapies. Recent key developments include SONATA announcing a new preventive care membership combining deep biological testing, whole-genome sequencing, clinical AI, and ongoing physician-led care. Illumina announced TruPath Genome, a new genomic offering aimed at setting a higher standard for genome-informed insights in research and clinical applications. Foundation Medicine introduced a whole-genome sequencing germline test for research use to support translational research and biomarker discovery beyond oncology. CENTOGENE launched CentoGenome Ultra-Fast, a rapid whole-genome sequencing solution with results in about 5 business days. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

The genomic biomarkers market is positioned for sustained growth driven by the convergence of precision medicine, technological innovation, and expanding healthcare investment. The transition from technology-driven adoption toward clinically integrated precision healthcare represents a fundamental shift in genomic medicine. While challenges related to high costs, reimbursement variability, and interpretation complexity persist, strategic investments in technology, partnerships, and evidence generation are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with genomic biomarkers evolving beyond single-disease applications into comprehensive platforms that integrate diagnosis, treatment selection, therapeutic monitoring, and population health management across global healthcare systems.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Global Genomic Biomarkers Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Industry Overview
3.3 Industry Evolution
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast Analysis (2026-2035)
3.7 Disease Burden and Clinical Significance of Genomic Biomarkers
3.8 Epidemiology and Disease Prevalence Analysis
3.9 Diagnosed Patient Population Analysis
3.10 Precision Medicine Adoption Landscape
3.11 Biomarker Testing Volume Analysis
3.12 Companion Diagnostics Landscape
3.13 Clinical Utility Across Therapeutic Areas

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Genomic Technologies
6.2 Biomarker Discovery and Validation Trends
6.3 Companion Diagnostic Innovation
6.4 Clinical Trial Analysis
6.5 Pipeline Analysis of Genomic Biomarker-Based Diagnostics
6.6 AI Integration in Genomic Biomarker Discovery and Interpretation
6.7 Multi-Omics and Digital Health Integration
6.8 Technology Roadmap

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Global Genomic Biomarkers Market Landscape Analysis

8.1 Analysis by Biomarker Type
8.2 Analysis by Technology Platform
8.3 Analysis by Sample Type
8.4 Analysis by Clinical Application
8.5 Analysis by Testing Methodology
8.6 Analysis by Therapeutic Area

9. Global Genomic Biomarkers Market Segment Analysis (2021-2035)

9.1 By Biomarker Type
- 9.1.1 DNA Biomarkers
- 9.1.2 RNA Biomarkers
- 9.1.3 Other Genomic Biomarkers
9.2 By Technology
- 9.2.1 Next-Generation Sequencing (NGS)
- 9.2.2 Polymerase Chain Reaction (PCR)
- 9.2.3 Microarray Analysis
- 9.2.4 Other Genomic Technologies
9.3 By Sample Type
- 9.3.1 Tissue Biopsy
- 9.3.2 Liquid Biopsy
- 9.3.3 Saliva and Buccal Swab
- 9.3.4 Other Biological Samples
9.4 By Clinical Application
- 9.4.1 Oncology
- 9.4.2 Rare Genetic Diseases
- 9.4.3 Cardiovascular Diseases
- 9.4.4 Neurological Disorders
- 9.4.5 Infectious Diseases
- 9.4.6 Autoimmune Disorders
- 9.4.7 Other Clinical Applications
9.5 By End User
- 9.5.1 Hospitals
- 9.5.2 Clinical Diagnostic Laboratories
- 9.5.3 Academic & Research Institutes
- 9.5.4 Others

10. Global Genomic Biomarkers Market Geographical Analysis (2021-2035)

10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 South America
10.5 Middle East & Africa

11. Global Genomic Biomarkers Market Country Analysis (2021-2035)

11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Italy
11.7 Spain
11.8 Japan
11.9 China
11.10 India
11.11 South Korea
11.12 Australia
11.13 Brazil
11.14 Mexico
11.15 Saudi Arabia
11.16 South Africa

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Strategic Developments
12.3 Mergers & Acquisitions, Partnerships & Collaborations
12.4 Product Launches

13. Company Profiles

13.1 Illumina, Inc.
- 13.1.1 Company Overview
- 13.1.2 Financials
- 13.1.3 Product Portfolio
- 13.1.4 Recent Developments
13.2 F. Hoffmann-La Roche Ltd.
13.3 Thermo Fisher Scientific Inc.
13.4 Natera
13.5 Tempus AI
13.6 Guardant Health, Inc.
13.7 Exact Sciences Corporation
13.8 Grail
13.9 Bio-Rad Laboratories, Inc.
13.10 Natera, Inc.